ISRG Quantitative Stock Analysis

Validea's guru fundamental report indicates that Intuitive Surgical (ISRG) receives a 75% rating based on their Multi-Factor Investor model, inspired by Pim van Vliet's low-volatility investment strategy, which considers momentum and net payout yields; while ISRG passes the market cap and standard deviation tests, it receives a neutral rating for momentum and net payout yield, ultimately failing the final rank within the strategy.

Analysis

Validea's fundamental report on Intuitive Surgical Inc. (ISRG) indicates a 75% rating based on its Multi-Factor Investor model, which emulates Pim van Vliet's strategy focusing on low volatility stocks with strong momentum and high net payout yields. ISRG, a large-cap growth stock in the Medical Equipment & Supplies sector, passed the model's tests for market capitalization and standard deviation. However, it received neutral ratings for "Twelve Minus One Momentum" and "Net Payout Yield." Consequently, despite the 75% score—where a score of 80% or above typically signals some interest and 90% strong interest—ISRG ultimately received a "FAIL" on the final rank within this specific investment strategy. The sentiment for ISRG is reported as mildly negative with a score of -0.3, and the market impact score is low at 0.2, suggesting the findings may not significantly sway broader market perception immediately.

Key Decisions for Investors

• Investors employing Validea's Pim van Vliet model or similar multi-factor strategies should note ISRG's 'FAIL' rank, primarily due to neutral scores on momentum and net payout yield, despite its favorable low volatility and market cap characteristics.
• The 75% rating, falling short of the 80% threshold for strategic interest under this model, suggests that ISRG may not currently be an optimal fit for portfolios strictly adhering to these specific combined factor criteria.
• Consider further due diligence on the drivers behind ISRG's neutral momentum and net payout yield before making investment decisions based solely on this particular factor-based screening.